Healthinvest Partners Ab sold 20,000 shares of the biopharmaceutical major Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter. Shares of Gilead Sciences have lost around 11% since the beginning of 2016 amid an overall market decline, even though the company delivered strong results for the last quarter with EPS of $3.32 beating the estimates of $3.00, while revenue of $8.51 billion was better than the expected $8.14 billion. According to many experts, Gilead Science current valuation is low taking into account its businesses and balance sheet and the fair value of its stock is significantly above the current levels. Another investor bullish on Gilead is John Armitage's Egerton Capital limited, which reported 4.29 million shares in its latest 13F filing.